- Home
- HQI vs CRVS Comparison
HQI vs CRVS Comparison
Compare HQI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HQI | CRVS |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.0M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HQI | CRVS |
|---|---|---|
| Price | $8.30 | $7.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $13.00 | ★ $13.75 |
| AVG Volume (30 Days) | 43.5K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ 412.84 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $31,691,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.17 | N/A |
| P/E Ratio | $17.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $2.54 |
| 52 Week High | $15.75 | $9.60 |
Technical Indicators
Market Signals| Indicator | HQI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 38.18 |
| Support Level | $7.38 | $8.31 |
| Resistance Level | $8.36 | $9.60 |
| Average True Range (ATR) | 0.59 | 0.57 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 68.99 | 6.81 |
Price Performance
Historical ComparisonAbout HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).